Research Contributors: Lori Klein, Rudiger Papsch, Hyein Grace Lee, and Elisabeth Mah
This is a preview of our latest whitepaper. Be sure to download the full piece below.
Medical Affairs teams often struggle to demonstrate their full strategic value by relying heavily on activity-based metrics rather than outcomes-oriented impact metrics.
Leveraging Putnam’s extensive experience with biopharmaceutical clients, this white paper provides practical, actionable guidance to help Medical Affairs leaders select, implement, and communicate impactful metrics. We present a pragmatic framework that enables Medical Affairs teams to position themselves as strategic drivers of patient outcomes, healthcare improvements, and overall organizational success, and ensure readiness for the era of Precision Medical Affairs.
Jump to a slide with the slide dots.
Discover how to select the right preference method DCE, BWS, MDT or OPUF for rare diseases and small sample studies.
Read moreExplore a new model for antibiotic investment—driven by AMR, evolving P&R frameworks, and key indicators shaping commercial strategy.
Read moreExplore how CMS set 2024 drug MFPs under the IRA—insights, data drivers & pharma strategies for future Medicare negotiations.
Read more